Summary LY-2183240 is a multifaceted compound known for its dual role as a robust inhibitor of both endocannabinoid anandamide reuptake and the enzyme fatty acid amide hydrolase (FAAH), responsible for anandamide degradation. This distinctive mechanism leads to a significant increase in anandamide levels within the brain, resulting in observed analgesic and anxiolytic effects in animal …
Summary JTE 7-31, a creation of Japan Tobacco, emerges as a selective agonist for cannabinoid receptors. This compound exhibits significant selectivity for CB2 receptors, yet it maintains a noteworthy affinity for CB1 receptors, boasting a Ki of 0.088nM at CB2 compared to 11nM at CB1. Identifiers CAS Number 194358-72-0 3D model (JSmol) Interactive image ChemSpider …
Summary JTE-907 is a pharmaceutical compound employed in scientific investigations, functioning as a discerning CB2 inverse agonist. This substance has demonstrated anti-inflammatory properties in animal experiments, with these effects believed to stem from an interplay between the CB2 receptor and IgE. Identifiers IUPAC name CAS Number 282089-49-0 PubChem CID 9867770 ChemSpider 8043461 UNII DAV3Q7SNOL CompTox …
Summary FUBIMINA, also recognized under the aliases BIM-2201, BZ-2201, and FTHJ, is a synthetic cannabinoid, constituting the benzimidazole counterpart to AM-2201. This compound has gained prominence as an active ingredient within synthetic cannabis blends. Its initial discovery took place in Japan in 2013, concurrently with the identification of MEPIRAPIM.FUBIMINA exerts its influence as a moderately …
Summary EG-018, a synthetic cannabinoid rooted in the carbazole structure, has found a niche in online markets as a designer drug. This compound is a partial agonist for CB1 and CB2 receptors, exhibiting a notably robust binding affinity. However, its effectiveness in eliciting a signaling response still needs to be higher. Identifiers IUPAC name CAS …
Summary CB-13, also known as CRA13 and SAB-378, is a cannabinoid pharmaceutical compound. This substance is a robust agonist for CB1 and CB2 receptors, yet it cannot breach the blood-brain barrier. Consequently, at lower doses, CB-13 primarily elicits peripheral effects, while indications of central effects, such as catalepsy, manifest only when administered at significantly higher …
Summary BIM-018 is a synthetic cannabinoid belonging to the benzimidazole family and is considered the analog of JWH-018. It is believed to act as a potent agonist of the CB2 receptor and has been marketed online as a designer drug.Other benzimidazole derivatives with a similar structure have demonstrated high selectivity as agonists for the CB2 …
Sumamry Initially synthesized by chemist Wayne E. Kenney, BAY 38-7271 (also known as KN 38-7271) is a pharmaceutical compound developed by Bayer AG. This drug is a cannabinoid receptor agonist, exhibiting analgesic and neuroprotective properties. BAY 38-7271 is primarily employed in scientific research and has shown promise for potential applications in treating traumatic brain injury.In …
Summary AB-CHFUPYCA, also known as AB-CHMFUPPYCA, is a compound initially discovered as part of synthetic cannabis products in Japan back in 2015. The name “AB-CHFUPYCA” is an abbreviation derived from its systematic name, N-(1-Amino-3-methyl-1-oxoButan-2-yl)-1-(cyclohexylmethyl)-3-(4-FlUorophenyl)-1H-PYrazole-5-CarboxAmide. Two distinct regioisomers of AB-CHFUPYCA exist: 3,5-AB-CHMFUPPYCA and 5,3-AB-CHMFUPPYCA. Both collectively refer to as AB-CHMFUPPYCA isomers, meaning that AB-CHMFUPPYCA and AB-CHFUPYCA …
Summary A-836,339, a product of Abbott Laboratories, is a potent full agonist of the cannabinoid receptor. Notably, it exhibits selectivity for CB2, with Ki values of 0.64 nM at CB2 compared to 270 nM at the psychoactive CB1 receptor. At lower doses, A-836,339 displays selective analgesic, anti-inflammatory, and anti-hyperalgesic effects. However, its high efficacy at …
